SenzaGen Q4 Initial take – Soft sales but solid cost control - Redeye

Redeye provides an initial take following the release of SenzaGen’s Q4 2024 report. Sales did not live up to our expectations; however, costs remain at solid levels. We will provide an update where we dig deeper into the report, and we expect to make downward sales adjustments.

Länk till analysen i sin helhet: https://www.redeye.se/research/1075823/senzagen-q4-initial-take-soft-sales-but-solid-cost-control?utm_source=finwire&utm_medium=RSS